A historical cohort investigation of 29 patients with comorbid mood disorder and obesity noted that liraglutide-induced weight loss over 6 months was not associated with changes in psychiatric symptoms, although less than half of the study population completed the study period 180
Clinical Evidence: Weight Loss, Glucose, and Metabolic Outcomes Phase 2b and Phase 3 trials published through 2024 demonstrate retatrutide's efficacy in weight loss and glycemic control
Further research is needed to fully understand its mechanisms of action, including its ability to improve mental stamina, and determine its potential therapeutic applications, particularly related to its ability to cross the blood-brain barrier and exert neurotrophic activity
Treatments such as Sofwave can also be performed throughout the weight loss journey to stimulate collagen production and help maintain skin firmness
Personalized genetic data transforms semaglutide management from reactive (waiting for problems to emerge) to proactive (anticipating individual needs and adjusting protocols accordingly)
Egeberg A, Weinstock LB, Thyssen EP et al
